- CiVentiChem completes a new facility, expanding its manufacturing capacity by 300%.
- The new plant will focus on producing Regulatory Starting Materials (RSMs) and intermediates for small molecule clinical and commercial needs.
CiVentiChem, a Contract Development and Manufacturing Organization (CDMO), has completed a new facility that significantly increases its manufacturing capacity by 300%. This expansion is aimed at producing Regulatory Starting Materials (RSMs) and intermediates, supporting both small molecule clinical and commercial needs.
Bhaskar Venepalli, CEO of CiVentiChem, described the expansion as a major evolution for the company, driven by customer demand and recent international developments. “The decision to invest in a second manufacturing plant was driven by our customers and recent international developments. We’ve seen an increasing number of clients seeking alternative manufacturers outside of China for RSMs and intermediates,” Venepalli said.
Founded in North Carolina in 1994, CiVentiChem initially focused on medicinal chemistry and FTE services. The company expanded its operations in 2001 by opening its first R&D facility in Hyderabad, India. In 2009, CiVentiChem began larger-scale manufacturing, producing RSMs for clinical programs and three commercial programs.
